• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Disposition of digitoxin in renal failure.

作者信息

Vöhringer H F, Rietbrock N, Spurny P, Kuhlmann J, Hampl H, Baethke R

出版信息

Clin Pharmacol Ther. 1976 Apr;19(4):387-95. doi: 10.1002/cpt1976194387.

DOI:10.1002/cpt1976194387
PMID:1269191
Abstract

The disposition of digitoxin was studied for a period of 8 days in 6 uremic patients given a single oral dose of 1 mg 3H-digitoxin. In plasma, the time-course of radioactivity indicated a diminished absorption velocity of tritium compared to that of control subjects already reported and, after reaching of a pseudostate-equilibrium at 24 hr, an exponential decline with a mean half-life of 8.0 days. In urine, smaller amounts of tritiated compounds were eliminated in uremic patients (8.7% of the dose) than in controls (22.5%). The average fecal excretion of digitoxin and its metabolites was not significantly increased. Chloroform extraction and thin-layer chromatography in plasma, urine and feces suggested no qualitative alteration in the metabolism of digitoxin. Calculations of the total body tritium content (body stores) after each 24-hr interval and its pharmacokinetic behavior showed that the elimination of digitoxin is determined by the transfer constant from tissue to plasma. The differences in elimination kinetics of digitoxin and its metabolites of uremic patients and healthy subjects were not significant.

摘要

相似文献

1
Disposition of digitoxin in renal failure.
Clin Pharmacol Ther. 1976 Apr;19(4):387-95. doi: 10.1002/cpt1976194387.
2
Metabolism and excretion of 3H-digitoxin in the rat.
Biochem Pharmacol. 1974 Sep 15;23(18):2567-75. doi: 10.1016/0006-2952(74)90179-8.
3
Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats.螺内酯预处理对大鼠中洋地黄毒苷药代动力学及代谢的影响。
Naunyn Schmiedebergs Arch Pharmacol. 1975;287(2):129-39. doi: 10.1007/BF00510445.
4
[Pharmacokinetics of digitoxin in chronic renal failure (author's transl)].
Dtsch Med Wochenschr. 1977 Jan 28;102(4):109-15. doi: 10.1055/s-0028-1104850.
5
Interruption of the enterohepatic circulation of digitoxin by cholestyramine. II. Effect on metabolic disposition of tritium-labeled digitoxin and cardiac systolic intervals in man.考来烯胺对洋地黄毒苷肝肠循环的阻断作用。II. 对人体中氚标记洋地黄毒苷代谢处置及心脏收缩间期的影响。
J Clin Invest. 1971 Dec;50(12):2638-44. doi: 10.1172/JCI106764.
6
Metabolism and excretion of digitoxin in man.
Clin Pharmacol Ther. 1974 Nov;16(5 Part 1):796-806. doi: 10.1002/cpt1974165part1796.
7
Studies on digitalis. XI. Digitoxin metabolism in patients with impaired renal function.
Clin Pharmacol Ther. 1977 May;21(5):536-46. doi: 10.1002/cpt1977215536.
8
Plasma concentration, uptake by liver, and biliary excretion of tritiated cardiac glycosides in the isolated perfused guinea-pig liver.离体灌注豚鼠肝脏中氚标记强心苷的血浆浓度、肝脏摄取及胆汁排泄
Br J Pharmacol. 1971 Apr;41(4):648-60. doi: 10.1111/j.1476-5381.1971.tb07073.x.
9
Studies on digitalis. IX. Some kinetic aspects of digitoxin metabolism.
Clin Pharmacol Ther. 1977 Mar;21(3):255-66. doi: 10.1002/cpt1977213255.
10
Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment.长期治疗期间洋地黄毒苷和地高辛药代动力学的个体间差异。
Eur J Clin Pharmacol. 1981 Jan;19(1):45-51. doi: 10.1007/BF00558383.

引用本文的文献

1
Digitoxin and its metabolites in patients with liver cirrhosis.
Eur J Drug Metab Pharmacokinet. 1993 Apr-Jun;18(2):207-13. doi: 10.1007/BF03188797.
2
Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.体外循环对药物药代动力学的影响。
Clin Pharmacokinet. 1982 May-Jun;7(3):234-51. doi: 10.2165/00003088-198207030-00004.
3
A standard approach to compiling clinical pharmacokinetic data.一种汇编临床药代动力学数据的标准方法。
J Pharmacokinet Biopharm. 1981 Feb;9(1):59-127. doi: 10.1007/BF01059343.
4
Disease-related alterations in cardiac glycoside disposition.心脏苷类药物处置的疾病相关改变。
Clin Pharmacokinet. 1982 Sep-Oct;7(5):434-51. doi: 10.2165/00003088-198207050-00004.
5
[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine].[β-乙酰地高辛和洋地黄毒苷与硝苯地平联合治疗的药代动力学及心脏效应]
Klin Wochenschr. 1984 May 15;62(10):451-7. doi: 10.1007/BF01726906.
6
On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.
Eur J Clin Pharmacol. 1983;25(3):369-73. doi: 10.1007/BF01037950.
7
Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.肾功能不全患者中强心苷类药物的临床药代动力学
Clin Pharmacokinet. 1983 Mar-Apr;8(2):155-78. doi: 10.2165/00003088-198308020-00003.
8
Clinical pharmacokinetics of digitoxin.洋地黄毒苷的临床药代动力学
Clin Pharmacokinet. 1977 Jul-Aug;2(4):292-311. doi: 10.2165/00003088-197702040-00005.
9
Relationship between dose and plasma level of digoxin and patient characteristics.
Eur J Clin Pharmacol. 1979 Mar 26;15(2):109-14. doi: 10.1007/BF00609873.
10
Drug kinetics and artificial kidneys.药物动力学与人工肾
Clin Pharmacokinet. 1977 Nov-Dec;2(6):403-26. doi: 10.2165/00003088-197702060-00002.